232 related articles for article (PubMed ID: 24631023)
1. Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
Körner Z; Fontes-Oliveira CC; Holmberg J; Carmignac V; Durbeej M
Am J Pathol; 2014 May; 184(5):1518-28. PubMed ID: 24631023
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice.
Carmignac V; Quéré R; Durbeej M
Hum Mol Genet; 2011 Feb; 20(3):541-52. PubMed ID: 21084425
[TBL] [Abstract][Full Text] [Related]
3. Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A.
Carmignac V; Svensson M; Körner Z; Elowsson L; Matsumura C; Gawlik KI; Allamand V; Durbeej M
Hum Mol Genet; 2011 Dec; 20(24):4891-902. PubMed ID: 21920942
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
Körner Z; Durbeej M
PLoS One; 2016; 11(1):e0146471. PubMed ID: 26731667
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice.
Bentzinger CF; Barzaghi P; Lin S; Ruegg MA
FASEB J; 2005 Jun; 19(8):934-42. PubMed ID: 15923403
[TBL] [Abstract][Full Text] [Related]
6. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
[TBL] [Abstract][Full Text] [Related]
7. CD90-positive cells, an additional cell population, produce laminin alpha2 upon transplantation to dy(3k)/dy(3k) mice.
Fukada S; Yamamoto Y; Segawa M; Sakamoto K; Nakajima M; Sato M; Morikawa D; Uezumi A; Miyagoe-Suzuki Y; Takeda S; Tsujikawa K; Yamamoto H
Exp Cell Res; 2008 Jan; 314(1):193-203. PubMed ID: 17963748
[TBL] [Abstract][Full Text] [Related]
8. Laminin α1 reduces muscular dystrophy in dy
Gawlik KI; Harandi VM; Cheong RY; Petersén Å; Durbeej M
Matrix Biol; 2018 Sep; 70():36-49. PubMed ID: 29544677
[TBL] [Abstract][Full Text] [Related]
9. Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD.
Moreira Soares Oliveira B; Durbeej M; Holmberg J
PLoS One; 2017; 12(8):e0181950. PubMed ID: 28771630
[TBL] [Abstract][Full Text] [Related]
10. Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A.
Yamauchi J; Kumar A; Duarte L; Mehuron T; Girgenrath M
Hum Mol Genet; 2013 Nov; 22(21):4306-17. PubMed ID: 23773998
[TBL] [Abstract][Full Text] [Related]
11. Loss of dystrophin and β-sarcoglycan significantly exacerbates the phenotype of laminin α2 chain-deficient animals.
Gawlik KI; Holmberg J; Durbeej M
Am J Pathol; 2014 Mar; 184(3):740-52. PubMed ID: 24393714
[TBL] [Abstract][Full Text] [Related]
12. Synaptic plasticity in the dy2J mouse model of laminin alpha2-deficient congenital muscular dystrophy.
Anderson JL; Head SI; Morley JW
Brain Res; 2005 Apr; 1042(1):23-8. PubMed ID: 15823249
[TBL] [Abstract][Full Text] [Related]
13. Early skeletal muscle pathology and disease progress in the dy
Gawlik KI; Körner Z; Oliveira BM; Durbeej M
Sci Rep; 2019 Oct; 9(1):14324. PubMed ID: 31586140
[TBL] [Abstract][Full Text] [Related]
14. Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.
Gawlik KI; Holmberg J; Svensson M; Einerborg M; Oliveira BM; Deierborg T; Durbeej M
Sci Rep; 2017 Mar; 7():44059. PubMed ID: 28281577
[TBL] [Abstract][Full Text] [Related]
15. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice.
Guo LT; Zhang XU; Kuang W; Xu H; Liu LA; Vilquin JT; Miyagoe-Suzuki Y; Takeda S; Ruegg MA; Wewer UM; Engvall E
Neuromuscul Disord; 2003 Mar; 13(3):207-15. PubMed ID: 12609502
[TBL] [Abstract][Full Text] [Related]
16. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.
Rooney JE; Knapp JR; Hodges BL; Wuebbles RD; Burkin DJ
Am J Pathol; 2012 Apr; 180(4):1593-602. PubMed ID: 22322301
[TBL] [Abstract][Full Text] [Related]
17. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.
Girgenrath M; Beermann ML; Vishnudas VK; Homma S; Miller JB
Ann Neurol; 2009 Jan; 65(1):47-56. PubMed ID: 19086074
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice.
van Lunteren E; Moyer M; Leahy P
Physiol Genomics; 2006 Mar; 25(1):85-95. PubMed ID: 16368874
[TBL] [Abstract][Full Text] [Related]
19. Expression of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal muscle of dystrophic 129ReJ dy/dy mice.
Ringelmann B; Röder C; Hallmann R; Maley M; Davies M; Grounds M; Sorokin L
Exp Cell Res; 1999 Jan; 246(1):165-82. PubMed ID: 9882526
[TBL] [Abstract][Full Text] [Related]
20. The zebrafish candyfloss mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient congenital muscular dystrophy.
Hall TE; Bryson-Richardson RJ; Berger S; Jacoby AS; Cole NJ; Hollway GE; Berger J; Currie PD
Proc Natl Acad Sci U S A; 2007 Apr; 104(17):7092-7. PubMed ID: 17438294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
